Zepbound Formulations and Dosage Strengths
Zepbound (tirzepatide) is available as a once-weekly subcutaneous injection in single-dose pens at the following strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg 1.
Available Dosage Strengths
The medication comes in six distinct formulations, all administered subcutaneously once weekly:
- 2.5 mg - Typically used as the initial starting dose
- 5 mg - First maintenance dose option
- 7.5 mg - Intermediate escalation dose
- 10 mg - Second maintenance dose option
- 12.5 mg - Higher escalation dose
- 15 mg - Maximum approved dose
Clinical Dosing Context
Based on guideline evidence, the maximum approved daily (weekly) doses used in clinical practice are 5 mg, 10 mg, or 15 mg once weekly 2. The 2.5 mg, 7.5 mg, and 12.5 mg strengths serve as dose-escalation steps to improve gastrointestinal tolerability during titration.
Typical Dosing Strategy
The standard approach involves:
- Starting at 2.5 mg weekly for 4 weeks
- Escalating through intermediate doses (5 mg → 7.5 mg → 10 mg → 12.5 mg) at 4-week intervals
- Reaching a maintenance dose of 5 mg, 10 mg, or 15 mg based on efficacy and tolerability
Recent evidence demonstrates that even lower maintenance doses (2.5 mg) combined with lifestyle modification can produce clinically meaningful weight loss (-15.3%) with better tolerability than higher doses 3, though this is not yet reflected in standard FDA-approved maintenance dosing.
Important Considerations
The inactive ingredients include benzalkonium chloride, edetate disodium, sodium chloride, sodium phosphate dibasic, and sodium phosphate monobasic 1. All formulations are provided as ready-to-use single-dose pens requiring no reconstitution or dilution.